Analyst Riccardo Lowi discusses Shield Therapeutics PLC’s (LON:STX) lead asset Feraccru - a novel and highly differentiated iron formulation, for oral administration, indicated for the treatment of iron deficiency.
Investor deep dive
Shield Therapeutics: All eyes on the US after FDA approval
Shield Therapeutics' Feraccru drug 'a potential game-changer'
Quick facts: Shield Therapeutics PLC
Price: 182.5 GBX
Market Cap: £213.87 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE